Innate Pharma S.A. (0EVI.L)

3,0281 +0,0442 (+1,48%) Al cierre: 06:19PM BST

Innate Pharma S.A.

117, Avenue de Luminy
BP 30191
Marseille 13009
France
33 4 30 30 30 30
https://www.innate-pharma.com

Sector(es): 
Sector: 
Empleados a tiempo completo: 179

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Herve Brailly Ph.D.	Co-Founder, Interim CEO & Chairman of Executive Board	N/A	N/A	1961
Mr. Yannis Morel Ph.D.	Executive VP, COO & Member of Executive Board	359,92k	N/A	1973
Dr. François Romagné Ph.D.	Founder	N/A	N/A	1964
Mr. Eric Vivier D.V.M., M.B.A., Ph.D.	Founder, Senior VP & Chief Scientific Officer	N/A	N/A	1964
Dr. Marc Bonneville Ph.D.	Founder	N/A	N/A	1960
Mr. Jean Jacques Fournié Ph.D.	Founder	N/A	N/A	N/A
Mr. Alessandro Moretta M.D., Ph.D.	Founder	N/A	N/A	N/A
Mr. Frederic Lombard M.B.A.	Senior VP & CFO	N/A	N/A	1975
Dr. Sonia Quaratino M.D., Ph.D.	Executive VP, Chief Medical Officer & Member of Executive Board	N/A	N/A	1967
Mr. Arvind Sood	Executive VP, President of US Operations & Member of Executive Board	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en EUR.

Descripción

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

Gobierno corporativo

El ISS Governance QualityScore de Innate Pharma S.A., a día 1 de mayo de 2024, es 9. Las puntuaciones base son Auditoría: 8; Tablero: 9; Derechos de los accionistas: 4; Compensación: 10.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.